GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Cash-to-Debt

ESLA (Estrella Immunopharma) Cash-to-Debt : No Debt (1) (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Estrella Immunopharma's cash to debt ratio for the quarter that ended in Jun. 2024 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Estrella Immunopharma could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Estrella Immunopharma's Cash-to-Debt or its related term are showing as below:

ESLA' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.88   Med: No Debt   Max: No Debt
Current: 13.88

During the past 4 years, Estrella Immunopharma's highest Cash to Debt Ratio was No Debt. The lowest was 13.88. And the median was No Debt.

ESLA's Cash-to-Debt is ranked better than
59.81% of 1493 companies
in the Biotechnology industry
Industry Median: 6.2 vs ESLA: 13.88

Estrella Immunopharma Cash-to-Debt Historical Data

The historical data trend for Estrella Immunopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Estrella Immunopharma Cash-to-Debt Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Cash-to-Debt
N/A No Debt No Debt No Debt

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt 73.79 No Debt No Debt No Debt

Competitive Comparison of Estrella Immunopharma's Cash-to-Debt

For the Biotechnology subindustry, Estrella Immunopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Cash-to-Debt falls into.



Estrella Immunopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Estrella Immunopharma's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Estrella Immunopharma had no debt (1).

Estrella Immunopharma's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Estrella Immunopharma had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Estrella Immunopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines